BioProcess International (BPI) 2026
Explore how we’re accelerating what's next in advanced therapies and how we can serve as your strategic partner for mRNA and viral vector programs.
September 22–25, 2026 | Boston, MA
BioProcess International (BPI) 2026
BioProcess International 2026—taking place September 22–25 in Boston, MA—will spotlight breakthroughs shaping the discovery, scale-up, and delivery of advanced therapies across five core pillars. The program features keynotes, sessions, workshops, and case-study forums that deliver practical strategies to improve quality, shorten timelines, and increase efficiency from early development through commercialization.
From cell line development and engineering to upstream processing and cell culture, downstream processing, digital biomanufacturing and data-driven operations, and CMC strategy and manufacturing performance, this event will cover a myriad of challenges facing drug developers today. Come discover how our integrated services and solutions can help you overcome obstacles and reduce risk on your journey to market.
Event details
Date: September 22–25, 2026
Format: In-person
Location: Hynes Convention Center, Boston, US
Event website: BioProcess International (BPI) | Conference and Exhibition | Official Event Website
Why Thermo Fisher Scientific?
Advanced therapies utilizing next-generation technologies such as mRNA and viral vectors are set to change the biopharmaceutical industry as we know it. As a leading CDMO and CRO partner, we’re excited to be at the forefront of innovation in this field, supporting our drug development partners through every phase of the journey to market—from early development through scale-up, manufacturing, and commercialization.
Through collaborative partnerships with biotechnology and pharmaceutical companies, we are helping accelerate what’s next in advanced therapies. By combining scientific expertise, trusted guidance, and proven execution, our end-to-end offerings help transform possibilities into products that benefit patients in need around the globe. We look forward to showcasing our capabilities at BioProcess International (BPI) 2026.
You’re invited: Technical presentation
Title: Harmonizing ex vivo lentivirus purification with in vivo purity expectations
Lentiviral vectors (LVVs) are critical for ex vivo and emerging in vivo gene therapies, yet scalable manufacturing remains limited by low infectious yields, process variability, and the need to balance vector recovery with impurity clearance. We developed an integrated manufacturing platform that combines high-throughput upstream process optimization with scalable downstream purification to address these challenges.
Join this presentation to learn how:
- High-throughput DoE and automated bioreactor platforms accelerate process optimization and enable successful scale-up to manufacturing-relevant systems.
- Optimized upstream processes achieve infectious titers approaching 1 × 10⁷ TU/mL while maintaining favorable infectivity-to-particle ratios.
- Application-specific purification strategies maximize infectious recovery for ex vivo therapies or enhance impurity clearance for in vivo applications.
- An integrated, scalable manufacturing platform can reduce development risk and support efficient clinical and commercial LVV production.
Session details:
- Date: September 22, 2026, Pre-Conference Day
- Location: Symposia 2: Intensified & Continuous Manufacturing
- Time: 10–10:30 a.m. ET
- Speaker: Pouria Motevalian, Director, Process Development
Let’s connect at BPI 2026
Schedule a meeting with Thermo Fisher Scientific at BioProcess International (BPI) 2026 to explore our integrated CDMO and CRO offerings, including services and solutions for mRNA and viral vector advanced therapy programs.
We look forward to seeing you soon.
Stay connected to new discoveries, innovations, and expert scientific opinions.
Follow us on social media for the latest up-to-date event happenings.
We look forward to seeing you soon